 
 
 
1 
  
KISA ÃœRÃœN B Ä°LGÄ°SÄ° 
 1. BEÅž ERÄ° TIBBÄ° ÃœRÃœNÃœN ADI  
 BUDERAT  400 mcg Ä°nhalasyon Ä°Ã§in Toz Ä° Ã§eren KapsÃ¼l   
 2. KALÄ°TATÄ° F VE KANT Ä°TATÄ° F BÄ°LEÅžÄ°M  
 Etkin madde :  
Budesonid     0.400 m g  
 
(*:-I6,I6*--.  
 Laktoz monohidrat    19.60 mg 
(Ä°>5;BNCN;1G>1;<U4UA   
-1A4U=3U=1445<5A9L9>S521;U>UH  
 3. FARMASÃ–T Ä°K FORM  
 Ä°nhalasyon tozu iÃ§eren sert kapsÃ¼ller  
Ä°Ã§erisinde s er2est a;UÅŸka>2eyaHC?H2D<D>a n, no: 3 2?yutunda ki ;UA=UHU -saydam sert jelatin 
kapsÃ¼ll er. 
 4. KLÄ°NÄ°K Ã–ZELLÄ° KLER  
 4.1. TerapÃ¶tik endikasyonlar  
BCU=U>CN=21B1=1;<1AU>411>C95>6<1=1CD1A2A?>;?49<1CMAB5=@C?=;?>CA?<NE5?A1<BC5A?9498C9G13U>U1H1<C=1;1=1L<U;D<<1>U<UA"&SC1C5;21 ÅŸU>1;D<<1>U<=1BUM>5A9<=5H  
 4.2. Pozoloji ve uygulama ÅŸ ekli  
 "8@85832=?0=5*6*;I45I ÄŸI>.;F:.;2  
 Dozaj, kiÅŸ9G5MH7N?<1A1;941=5C541E9B99L9>75A5;5>5>4NÅŸ N;4?H11G1A<1>=1<U4UA
D45B?>9485A7N>4NH5><9?<1A1;1<U>=1<U4UA9A81BC129A9>81<1BG?>3981HU>41>49 ÄŸerine 
geÃ§irilirken, doz ki ÅŸ9G5MH7N?<1A1;C5;A1AC9CA5549<=5<949A  
 
BronÅŸ2?*5*;<I6  tedavisi:  
 YetiÅŸkinler  
16961BCU=81BC1<UÄŸU?<1>G5C9ÅŸ ;9><5A9>C541E9B97N>45

=9;A?7A1=?<1>=9>9=D=5C;9<9
4?H4121ÅŸ<1CU<129<9A%?A=1<941=54?HD7N>459;94561

- 

=9;A?7A1=4UA7N>45

-
800 mikrograma e ÅŸdeÄŸ5AÅž9445C<91BCU=1C1;<1AUBUA1 BU>4181BC1?A1<;?AC9;?BC5A?94
C541E9B9>45>2D45B?>949>81<1BG?>C541E9B9>575L9A9<9A;5>E5G1?A1<;?AC9;?BC5A?94C541E9
4?HD1H1<CU<4U ÄŸU>417N><N;4?H- S52M<N>5A5;

=9;A?7A1=1;141AGN;B5<C9<529<9A   
 A8,=45*:?*ÅŸ >.F@.:2  
16961BCU=81BC1BUL?3D;<1A41C541E9G57N>4529A4561

=9;A?7A1=9<521 ÅŸ<1>129<9A
%?A=1<941=54?HD7N>459;94561

=9;A?7A1=4UA7N>45

=9;A?7A1=15 ÅŸdeÄŸ5A> 
 
 
 
 GN;B5;7N><N;4?H

=9;A?7A1=4UA BUDERAT eriÅŸkinlerin  45>5C9=91<CU>41
;D<<1>U<=1 <U4UAÄ°>81<5AU>  ;D<<1>U=UL?3DÄŸun inhaleri doÄŸAD29A ÅŸ5;9<45;D<<1>129<=5B9>5
21ÄŸ<U4UA  
 
6 yaÅŸU>1<CU>41;981BC1<1A41;<9>9;45>5G9=?<=14U ÄŸU>41> BUDERAT 2D yaÅŸ7AD2D>41;9
81BC1<1A41;D<<1>U<=1=1<U4UA  
 
:87248+;<:F4<2/*4,2 ÄŸ.:1*;<*5I ÄŸI7I7!<. davisi:  
D81BC1<U;9L9>M>5A9<5>4?H7N>454561

=9;A?7A1=4UA  
 
"&S  C1C5;21ÅŸ U>1;D<<1>U<=1BUM>5A9<=5H  
 BUDERAT reÃ§ete edilmi ÅŸ?A1<;?AC9;?BC5A?94;D<<1>1>"&S  <U81BC1<1A41?A1<4?H
1H1<CU<UAB1Q'?H?<?:9E5DG7D<1=1 ÅŸekli: Bron ÅŸ9G1<1BCU=C541E9B9R21 ÅŸ<U;<U2M<N=4525<9AC9<5>
4?HM>5A9<5A9G1@U<=1<U4UA  
 Uygulama ÅŸekli:  
BUDERAT, sadece ?A1<9>81<1BG?>9L9>49AE5B14535  inhal er 9<5C1C29;549<=5<949A  
 
"1>49415>65;B9G?>DA9B;9>91H1<C=1;9L9>85ADG7D<1=141>B?>A11 ÄŸHU>BD9<59G935
Ã§a<;1<1>=1BUE5CN;NAN<=5B9M>5A9<=5;C549A;HM<N=E5M<N=GAU311 ÄŸHU>BD
9<5L1<;1<1>=1BU2? ÄŸ1H9AA9C1BG?>D>D5>75<<5=5G5E5B9BC5=9;5C;9A9B;9>9>1H1<CU<=1BU>1
G1A4U=3U?<129<9A  
 
*5;29A;1@BN<45;95>4NÅŸ N;4?H

=9;A?7A1=4UA

=9;A?7A1=41>41814NÅŸ N;29AC5;
4?H75A5;9G?AB12DNAN>;D<<1>U<1=1H  
 
Ä°<13U>4?ÄŸAD?<1A1;DG7D<1>4U ÄŸU>UC5=9>5C=5;9L9>85;9=E5G121 ÅŸ;129AB1ÄŸ<U;
@A?65BG?>5<9  
 Ä°<13U>1;39 ÄŸ5A45;9854562M<75<5A5 ulaÅŸacaÄŸU>U71A1>C95C=5;NH5A5;D<<1>=1
C1<9=1C<1AU>17MA5 9>81<5AU>  doÄŸAD;D<<1>U=U>U81BC1G17MBC5A=5<949A  
 1BC1G1;1@BN<<5A9>B145359>81<1BG?>9<5;D<<1>U=9L9>?<4DÄŸD>DE5GDCD<=1=1BU
gerektiÄŸ9>9BMG<5=5<949A2;HM<N=  
 GAU>CU<U;D<<1>=1  ;U<1EDHD81BC1;D<<1>=1C1<9=1CU>41G5A1<=1;C14UA  
 B@.5989F5*;?875*:*252 ÅŸkin ek bilgiler:  
 BÃ¶brek yetmezli ÄŸi:  
M2A5;G5C=5H<9 ÄŸ9?<1>81BC1<1A41;<9>9;L1<UÅŸ =12D<D>=1=1;C14UA&A1<2D45B?>949<55<45
edilmiÅŸ ?<1>61A=1;?;9>5C9;E5A9<5AU ÅŸUÄŸU>412u tÃ¼r hastalarda sistemik maruziyetinin klinik 
?<1A1;1><1=<U4NH5G<5A4545ÄŸi ÅŸ=5B9?<1BU45 ÄŸ9<49A2;HM<N=1A=1;?<?:9;MH5<<9;<5A   
 
*:*,2ÄŸer yetmezli ÄŸi:  
KaraciÄŸer yetmezli ÄŸ9?<1>81BC1<1A41;<9>9;L1<UÅŸ =12D<D>=1=1;C14UA>31;2D45B?>94
aÄŸUA<U;<U?<1A1;85@1C9;=5C12?<9H=19<51CU<4UÄŸU>41> ÅŸiddetli karaci ÄŸer yetmezli ÄŸi olan 
hastalarda BUDERAT ;D<<1>U=U BUA1BU>4149;;1C<9?<D>=1<U4UA&A1<2D45B?>949<55<45
edilmiÅŸ ?<1>61A=1;?;9>5C9;E5A9<5AU ÅŸUÄŸU>41816969<1?AC1 ÅŸiddetli karaci ÄŸer yetmezl iÄŸi olan  
 
 
3 
 81BC1<1A419<13U>B9BC5=9;=1ADH9G5C9>9>;<9>9;?<1A1;1><1=<U4NH5G4545 ÄŸiÅŸ=5B9?<1BU
deÄŸ9<49A2;HM<N=1A=1;?<?:9;MH5<<9;<5A  
 
 
".-2?*<:24989F5*;?87 16961BCU=81BC1BUL?3D;<1A41C541E9G57N>4529A4561


=9;A?7A1=9<521 ÅŸ<1>129<9r. 6 ya ÅŸE5NH5A9>45;9L?3D;<1A41>?A=1<941=54?HD7N>459;9
4561

=9;A?7A1=4UA7N>45

=9;A?7A1=15 ÅŸdeÄŸ5AI?3D;<1A41M>5A9<5>5>GN;B5;
7N><N;4?H

=9;A?7A1=4UA BUDERAT, eri ÅŸkinlerin  7MH5C9=91<CU>41;D<<1>U<=1<U4UA
Ä°>81<5AU>  ;D<<1>U=UL?3D;<1AU>9>81<5A94?ÄŸAD29A ÅŸ5;9<45;D<<1>129<=5B9>521 ÄŸ<U4UA  
 6 yaÅŸU>1<CU>41;9L?3D;<1A41;<9>9;45>5G9=?<=14U ÄŸU>41> BUDERAT 2D yaÅŸ7AD2D>41;9
81BC1<1A41;D<<1>U<=1=1<U4UA  
 
.:2?*<:24989F5*;?87 G1ÅŸE5NH5A981BC1<1A41;<9>9;L1<U ÅŸ=12D<D>=1=1;C14UA  
 4.3. Kontrendikasyonlar  
 
 C;9>=14452D45B?>945G141G1A4U=3U=1445<5A9>45>85A81>7929A9>5;1A ÅŸU29<9>5>
aÅŸUAU81BB1B9G5CC5;HM<N=  
 ;C961;39 ÄŸ5ACN25A;N<?H<D81BC1<1A41;?>CA5>49;549A  
 B@.54=55*7I6=?*:I5*:I>.E75.65.:2  
 Ä°nhaler steroidin kombine edildi ÄŸ2!H  5I25.:2?* ÅŸ hastalarda pnÃ¶moni riski 
artabilmektedir.  
 
%.-*>27279:8/25*4<2472<.52ÄŸ i  
1BC1<1A19>81<52D45B?>94C541E9B9>9>@A?69<1;C9;>9C5<9 ÄŸ9E5B5=@C?=<1AU?<=14UÄŸU>4129<5
4NH5><9?<1A1;1<=1<1AU75A5;C9 ÄŸ91><1CU<=1<U4UAD45B?>941;DC2A?>;?B@1H=U?AC141>
;1<4UA=1BC1CDB1BC=1C9;DBE5G149ÄŸ5A1;DC1BCU=	"&1C1;<1AU>41DG7D<1>=1BU75A5;5>29A9>39<C541E945 ÄŸildir.  
 EÅŸlik eden durumlar  
Sessiz seyreden akci ÄŸeACN25A;N<?HD?<1>E5G1B?<D>D=G?<<1AU>416D>71<E5E9A1<
5>65;B9G?>D?<1>81BC1<1A4149;;1C<9;D<<1>U<=1<U4UA  
BronÅŸ5;C1H9E5@>M=?;?>G?H79291;39 ÄŸ5A81BC1<U;<1AU?<1>81BC1<1AUC541E9545A;5>6D>71<
5>65;B9G?>?<1BU<U ÄŸU7MHM>N>51<U>=1<U4UA  
 ;<I6*<*45*:I  
BCU=U>1;DC1C1;<1AUBUA1BU>41 BUDERAT dozunda  1ACUÅŸ1E5G1;UB1BNA5<9?A1<
;?AC9;?BC5A?94<5A<5E5	E5G15 ÄŸ5A29A5>65;B9G?>E1AB11>C929G?C9;<59<1E529AC541E9G5
75A5;B9>9=4DGD<129<9A  
 
1BC1<1A1;DC1BCU=B5=@C?=<1AU>U81696<5C=5;9L9>;DAC1A U3U9<1L?<1A1;85AH1=1>
G1><1AU>41;UB15C;9<929A9>81<52A?>;?49<1CMA2D<D>4DA=1<U4UA  
 
1BC1<1A11BCU=<1AU;MCN<5 ÅŸtiÄŸ9C1;49A45;UB15C;9<99>81<52A?>;?49<1CMAC541E9B9>9>
DG7D<1>=1BU;<U ÄŸU>411ACU ÅŸG1419>1CLUB?<D>D=B5=@C?=<1AU4?;C?A<1AU9<5 temasa  
 
 
4 
 75L=5<5A9M>5A9<=5<949A1BC1G5>945>45 ÄŸ5A<5>49A9<=5<9E51>C99>6<1=1CDE1AC541E9451ACUÅŸ  
75A5;B9>9=99>81<5G141?A1<;?AC9;?BC5A?944?HD>D>1ACUAU<=1BU4NÅŸ Ã¼nÃ¼lmelidir.  
 
 
Paradoksal bronkospazm  
%149A4DAD=<1A419>81<1BG?>4?HDG7D<1>=1BU>UC 1;925>2A?>;?B@1H=1G?<1L129<9A
'1A14?;B1<2A?>;?B@1H=75<9 ÅŸmesi durumunda BUDERAT inhalasyonu 45A81<;5B9<=5<9E5
75A5;9AB521ÅŸ ;129AC541E99<545 ÄŸiÅŸC9A9<=5<949A'1A14?;B1<2A?>;?B@1H=8UH<U5C;97MBC5A5>
29A9>81<52A?>;?49<1CMA5G1>UCE5A=5;C549A  
 Sistemik etkiler  
Ä°>81<5;?AC9;?BC5A?94<5AMH5<<9;<5DHD>BNA5<9?<1A1;GN;B5;4?H<1A41A5L5C5549<49 ÄŸinde, 
B9BC5=9;5C;9<5A?AC1G1LU;1A129<9AD5C;9<5A?A1<;?AC9;?BC5A?94<5A<5  G1@U<1>C541E945
7MAN<5>45>L?;41811H?AC1G1LU;1A&<1BUB9BC5=9;5C;9<5A1A1BU>4114A5>1<BD@A5BG?>89@5A14A5>?;?AC9B9H=	DB89>7B5>4A?=DL?3D;<1A41E55A75><5A452NGN=575A9<9 ÄŸi, kemik 
mineral yo ÄŸunluÄŸD>411H1<=1;1C1A1;CE57<?;?=1 ÅŸUAU4DG1A<U<U;A51;B9G?><1AUE54181
>149A?<=1;NH5A5@B9;?=?C?A89@5A1;C9E9C5DG;D2?HD;<D;<1AU1>;B9G5C545@A5BG?>E5
B1<4UA71><U;792929A49H9@B9;?<?:9;G14141EA1>U ÅŸB1<5C;9<5AMH5<<9;<5L?3D;<1A41G5A
1<=1;C14UAD>545><59>81<5;?AC9;?BC5A?944?HD>D> etkin ÅŸ5;9<451BCU=;?>CA?<N>N>
saÄŸ<1>4UÄŸU5>4NÅŸ N;4?H11G1A<1>=1BUM>5=<949A;HM<N=  
 F?F6.F@.:27-.42.<42  
D45B?>94L?3D;<1A41E514?<5B1><1A41MH5<<9;<5GN;B5;4?H41E5DHD>BNA5<9;D<<1>U=412NGN=5G9BN@A5B554529<9A+HD>BNA5<9?<1A1;  9>81<5;?AC9;?BC5A?94C541E9B97MA5>
L?3D;<1AU>2?G<1AU>U>4NH5><9?<1A1;M<LN<=5B9M>5A9<=5;C549ANGN=545G1E1 ÅŸlama oldu ÄŸu 
C1;49A45C541E99>81<5;?AC9;?BC5A?944?HD>D>=N=;N>B51BCU=;?>CA?<N>N>5C;9> ÅŸekilde 
saÄŸ<1>4UÄŸU5>4NÅŸ Ã¼k doza indirilmesi ama 3UG<17MH45>75L9A9<=5<949AGAU3181BC1>U>29A
@549G1CA9;B?<D>D=81BC1<U;<1AUDH=1>U>1B5E;549<=5B94NÅŸ Ã¼nÃ¼lmelidir. YetiÅŸ kinlerde 
ulaÅŸU<1>2?GNH5A9>45;95C;9454189<?<=1;NH5A575<9 ÅŸ9=8UHU>419>81<5;?AC9;?BC5A?94<5A<5
iliÅŸ;9<92D1H1<=1>U>DHD>  E145<95C;9<5A929<9>=5=5;C549A&A1<9>81<5;?AC9;?BC5A?94
C541E9B9>9>;5B9<=5B9>9C1;925>2NGN=5G9QG1;1<1=1R@?C1>B9G5<9G5C5A9>359>35<5>=5=9ÅŸ tir.  
 
EÅŸ@*6*75I4=55*7I5*725*D5*:  
BUDERAT E5 7NL<N29A-'9>8929CMAN>N>MA>5 ÄŸ9>9CA1;?>1H?<1C1H1>1E9A
;5C?;?>1H?<A9C?>1E9A>5<69>1E9A1=9?41A?>E5;<1A9CA?=9B9>DHD>BNA55 ÅŸH1=1><U
DG7D<1=1BUBUA1BU>4149;;1C<9?<D>=1<U4UA2;HM<N=  
 Tedaviye steroidler ile ba ÅŸlayan hastalar  
*5A1@MC9;5C;975>5<<9;<5
7N>9L5A9B9>455<45549<=5;C549A  AÅŸUAU2A?>ÅŸ iyal mukus 
B5;A5BG?>D?<1>81BC1<1A41C541E9>9>21 ÅŸ<1>7U3U>41G1;<1 ÅŸU;816C17929;UB129ABNA5?A1<
;?AC9;?BC5A?94C541E9 B9C541E9G55;<5>529<9A  
 
Steroide ba ÄŸI65I85*71*;<*5*:  
&A1<BC5A?94<5A45>2D45B?>94575L9<9A;5>81BC17MA535?<1 A1;BC129<29A4M>5=45?<=1<U4UA
YaklaÅŸ U;
7N>2?GD>314181M>3545>;D<<1>U<1>?A1<BC5A?94<529A<9;C5GN;B5;4?H
2D45B?>94;?=29>1BG?>DE5A9<9A&A1<4?H4181B?>A1;145=5<9?<1A1;1H1<CU<1A1;MA>5 ÄŸin 
85A1G ,=7@A54>9H?<?>E5G15 ÅŸdeÄŸ5A9?A1>U>41 mÃ¼mkÃ¼n olan en dÃ¼ÅŸ Ã¼k dÃ¼zeye 
indirilmelidir. Ä°<1E5B9BC5=9;;?AC9;?BC5A?94<5AG141 BUDERAT ile G1@U<1>C541E91>945>
deÄŸ9<G1E1ÅŸÃ§a kesilmelidir.  
  
 
 
 
 *A1E=135AA189E5G11ÄŸUA5>65;B9G?><1A7929MH5<;A9H4DAD=<1AU>1;1A ÅŸU;?G=11=13UG<1
81BC1>U>14A5>?;?AC9 ;1<A5H5AE9>9>G5C5A<94NH5G45?<4DÄŸundan emin olmak iÃ§in sistemik 
;?AC9;?BC5A?94<5A45>2D45B?>94575L9<5>9<;1G<1A2?GD>31MH5<<9;<549;;1C<9?<D>=1<U4UA
9@?C1<1=9; -pitÃ¼iter -14A5>1<'5;B5>6?>;B9G?><1AU4NH5><9?<1A1;9H<5>=5<949A1HU
81BC1<1A2 D79294DAD=<1A415;BCA1;?AC9;?BC5A?9445BC5 ÄŸ9>598C9G1L4DG=1;C14UA2D7929
81BC1<1AU>@?C1>B9G5<394494DAD=<1AU>U29<49A5>29ADG1AU;1ACU>UG1><1AU>41C1 ÅŸU=1<1AUC1EB9G5
549<=5;C549A)9BC5=9;;?AC9;?BC5A?94<5AG5A9>52D45B?>94575L9<=5B94181M>35B istemik 
;?AC9;?BC5A?94<5AC1A16U>41>21B;U<1>=U ÅŸ?<1>1<5A:9;A9>9CE5G157H5=179291<5A:9<5A9>?AC1G1
LU;=1BU>1G?<1L129<9A81BC1<1A41<5C1A:9;1BE5G15;<5=1ÄŸAUBUE521H5>45=9452D<1>CUBUE5;DB=17MAN<529<9AD79291<5A:9<5A<?;1<DG7D<1>1>1>C 989BC1=9>9;<5AE5G1
;?AC9;?BC5A?94<5A<5DG7D>29A ÅŸ5;9<45C541E9549<=5<949A<5A  
 
Ä°lave Ã¶nlemler  
&A1<;1>4949G1H9B9M><5=5;9L9>81BC1<1A185ADG7D<1=141>B?>A11 ÄŸHU>UBD9<5L1<;1<1=1BU
M>5A9<=5<949AMG<529A4DAD=75<9 ÅŸtiÄŸi takdirde, Ã§o ÄŸDE1;1415>6 eksiyon, BUDERAT 
C541E9B9  ;5B9<=5;B9H9>C?@9;1<1>C96D>71<C541E9G5G1>UCE5A535;C9A2;HM<N=E5
M<N=  
 9B6?>9?<DÅŸ 129<9A61;1CC541E9G51A1E5A9<=5B9G1414?HD>1H1<CU<=1BU>UE5	E5G1B5B9>
49><5>49A9<=5B99<5;?<1G<U;<175A94M>NÅŸ CNAN<529<9A49A2;HM<N=  
 
*<*5I=?0=5*6*?85=  
BUDERAT kapsÃ¼lleri , inhalasyon 3981HU>1;?G=1;G5A9>5G1><U ÅŸ<U;<1GDC1>81BC1<1A1419A
29<49A9=<5A1<U>=UÅŸ CUA"1@BN<<5A9>G1><UÅŸ <U;<1GDCD<=1BU4DAD=<1AU>U>2NGN;L?ÄŸunluÄŸu 
85A81>7929AG1>5C;99<59<9 ÅŸkilendirilmemiÅŸ tir. SaÄŸ<U;L1<UÅŸ 1><1AU81BC1G1 BUDERAT S9>
doÄŸAD;D<<1>U=U>U1><1C=1<U4UA2;H2M<N= ÄŸer BUDERAT reÃ§ete 549<5>29A81BC1>U>
solunumunda dÃ¼zelme ya ÅŸ1>=UG?AB1B1 ÄŸ<U;L1<UÅŸ 1><1AU81BC1G1 BUDERAT S9>1BU<
;D<<1>4UÄŸU>UB?A=1<U4UA  
 Ka@BN<<5A<1;C?H9L5A=5;C549A%149A;1<UCU=B1<71<1;C?H9>C?<5A1>BU#1@@<1;C?HG5C=5H<9ÄŸi 
ya da glikoz -71<1;C?H=1<12B?A@B9G?>@A?2<5=9?<1>81BC1<1AU>2D9<13U;D<<1>=1=1<1AU
gerekir.  
  
4.5. DiÄŸ.:<I++2F:F75.:25..<425.ÅŸ imler ve di ÄŸer etkileÅŸ im ÅŸekilleri  
 
CYP34A inhibisyonu yapan ajanlar  
 D45B?>949>1>1=5C12?<9H=1G?<DB9C?;A?='
-'9H?5>H9=-'
1A13U<UÄŸUG<14UA-'9>8929CMA<5A9?<1A1;29<9>5>9<1L<1AMA>5 ÄŸ9>9CA1;?>1H?<
1C1H1>1E9A;5C?;?>1H?<A9C?>1E9A>5<69>1E9A 1=9?41A?>;<1A9CA?=9B9>9<55 ÅŸH1=1><U
DG7D<1=1BU2D45B?>94=5C12?<9H=1BU>U9>89255CC9 ÄŸ9E54?<1GU BUG<1B9BC5=9;=1ADH9G5C9
1ACUA4UÄŸU29<9>=5;C549AD45B?>94  E529<9>5>-'9>8929CMA<5A9>9>29A<9;C5;D<<1>U=U>41
49;;1C<9?<D>=1<U4UA ÄŸ5A2DNAN><5A29A<9;C5DG7D<1>UG?AB114A5>1<;?AC9;1<6?>;B9G?>
9H<5>=5<9E52D45B?>949>4?HDG1>UC17MA51G1A<1>=1<U4UA;HM<N=E5M<N=  
 
 
 
 
  
 
 
6 
 ("27-F4;2? onu yapan ajanlar  
D45B?>949>7NL<N-'9>4N;<5G939<5A<5MA>A961=@9B9>5 ÅŸH1=1><U?<1A1;
;D<<1>U<=1BU2D45B?>94=5C12?<9H=1BU>U8UH<1>4UA129<9AE5B9BC5=9;=1ADH9G5C9>94N ÅŸNA529<9A
;HM<N=  
 
B@.5989F5*;?875*:*252 ÅŸkin ek bilgiler  
Ã–zel @?@N<1BG?><1A1MH7N5C;9<5 ÅŸ9=L1<UÅŸ =1BUGNANCN<=5=9ÅŸ tir.  
 
".-2?*<:24989F5*;?87  
'549G1CA9;@?@N<1BG?>1MH7N5C;9<5 ÅŸ9=L1<UÅŸ =1BUGNANCN<=5=9ÅŸ tir.  
 
.+.524>.5*4<*;?87  
 Genel tavsiye  
525<9;;1C57?A9B9  
 
A8,=4-8 ÄŸ=:6*98<*7;2?.52+=5=7*74*-I nlar/DoÄŸ=6487<:85F87<:*;.9;2?87  
I?3D;4?ÄŸDA=1@?C1>B9G5<92D<D>1>;14U><1A9L9>MH5<29AM>5A92D<D>=1=1;C14UA  
 
Gebelik dÃ¶nemi  
.?AD><D?<=14U;L17525<9;BUA1BU>41;D<<1>U=U>41>;1LU>U<=1<U4UA525<9;BUA1BU>417<D;?;?AC9;?BC5A?94C541E9B9;1LU>U lmazsa, oral glukokortikosteroidlerin yerine, dÃ¼ÅŸ Ã¼k 
B9BC5=9;G1>5C;9<5A9>545>9G<59>81<57<D;?;?AC9;?BC5A?94<5AC5A398549<=5<949A525;14U><1A1E5A9<9A;5>C5429A<9?<D>=1<U4UA  
 Laktasyon dÃ¶nemi  
Ä°>81<52D45B?>94 1>>5BNCN9L9>5B1<7U<1>UA525;<5A45D<1 ÅŸU<1>@<1H=1
;?>B1>CA1BG?><1AU>U>=1C5A>1<@<1H=1BU>412D<D>1>;?>B1>CA1BG?><1AU>G1;<1 ÅŸU;	

SN>5
ulaÅŸ=1BU25;<5>9A2;HM<N=1A=1;?<?:9;MH5<<9;<5AD4NÅŸ N;2D45B?>94=9;C1A<1AU
BUDERAT SUn laktasyon 4M>5=9>45;D<<1>U<129<535 ÄŸini dÃ¼ÅŸ N>4NA=5;<529A<9;C5DHD>BNA5<9
C541E9BUA1BU>415=H9A9<5>2525;<5ANH5A9>45;9;<9>9;5C;929<9>=5=5;C549A  
 
Ãœreme yeteneÄŸi / Fertilite  
D45B?>94;D<<1>U=U>U>9>B1>65AC9<9C5B9NH5A9>45;95C;9<5A981;;U>4185A81>7929A E5A9
2D<D>=1=1;C14UA  
 :*D>.6*427.4=55*7I6IF@.:27-.42.<425.:  
BUDERAT, araÃ§  E5=1;9>5;D<<1>ma yeteneÄŸini etkilemez.  
 
4.8. Ä°stenmeyen etkiler  
4E5AB9<1LA51;B9G?><1AU$54(S>U>B9BC5=?A71>BU>U6U>17MA5<9BC5<5>=5;C549A5A29Asistem or 71>BU>U6U9L5A9B9>4514E5AB9<1LA51;B9G?><1AUBU;<U ÄŸ17MA5BUA1<1>=1;C1?<D@5>BU;
7MAN<5>A51;B9G?><1A21 ÅŸC1<9BC5<5>=5;C549AGAU3185A29A14E5AB9<1LA51;B9G?>D9L9>
aÅŸaÄŸU41;9B9BC5=57MA5 &$)   A51;B9G?><1A1;1A ÅŸU<U;75<5>BU;<U;;1C57?A9B i de 
25<9AC9<=5;C549A  
I?;G1G7U> â‰¥	
G1G7U> â‰¥	

9<1	
G1G7U>?<=1G1> â‰¥	


9<1	


seyrek (â‰¥	



9<1	


L?;B5GA5;	



29<9>=9G?A5<45;9E5A9<5A45>
81A5;5C<5C18=9>549<5=9G?A  
   
 
 
7 
 7/.4;2?875*:>..7/.;<*;?8nlar  
-1G7U>  
AÄŸUH-GDC1;C1;1>49415>65;B9G?>D  
 
 
BaÄŸIÅŸI45I4;2;<.621*;<*5I45*:I  
Seyrek:  
AÅŸUAU4DG1A<U<U;A51;B9G?><1AU45A=1C9C5A9C5=4M;N>CNNAC9;5A1>:9G?M45=;1 ÅŸU>CU
1>169<1;C9;A51;B9G?><1A  
 
7-84:271*;<*5I45*:I  
Seyrek:  
Adrenal BD@A5BG?>DB89>7B5>4A?=D89@5A14A5>?;?AC9B9H=89@?;?AC9B9H=L?3D;<1A41E5
5A75><5A452NGN=575A9<9 ÄŸi.  
 
";242?*<:241*;<*5I45*:I  
Seyrek:  
Depresyon, huzursuzluk.  
 I?;B5GA5;  
Sinirlilik.  
 
E@1*;<*5I45*:I  
Seyrek:  
Katarakt, glokom.  
 Solunum, gÃ¶ ÄŸF;+8@=45=45*:I>.6.-2*;<27*51*;<*5I45*:I  
-1G7U>  
Ã–ksÃ¼rÃ¼k.  
 Seyrek:  
'1A14?;B1<2A?>;?B@1H=49B6?>92?ÄŸaz iritasyonu.  
 
Kas-2;4.5.<+8@=45=45*:I+* ÄŸ-84=>.4.6241*;<*5I45*:I  
Seyrek:  
Kemik mine ral yoÄŸunluÄŸunda azalma.  
 
Pazarlama son :*;I-.7.?26-.7*->.:;25*D:.*4;2?875*:I;I45I45*:+252762?8:  
AÅŸaÄŸU41;914E5AB9<1LA51;B9G?><1AU BUDERAT ile edinilmiÅŸ ?<1>@1H1A<1=1B?>A1BU
45>5G9=45>LU;1AU<=U ÅŸCUADA51;B9G?><1A2NGN;<NÄŸN25<9A<9?<=1G1>29A@?@N<1BG?>41>
7M>N<<N<N;21HU>4129 ldirilmiÅŸ  olduÄŸD>41>2D><1AU>BU;<U;<1AU>U7NE5>9<9A29A ÅŸekilde tahmin 
5C=5;=N=;N>?<=1=1;C14UAE52D>545><5Q29<9>=9G?AR?<1A1;BU>U6<1>4UAU<=1;C14UA  
 BaÄŸIÅŸI45I4;2;<.621*;<*5I45*:I  
"?>C1;C45A=1C9C*9@ ,/7539;=9ÅŸ ] aÅŸUAU4DG1A<U<U;A51;B9G?>D   
 
";242?*<:241*;<*5I45*:  
'B9;?=?C?A89@5A1;C9E9C5DG;D2?HD;<D;<1AU41EA1>U ÅŸ deÄŸiÅŸiklikleri (a ÄŸUA<U;<U?<1A1;
L?3D;<1A41  
  
 
 
8 
 +HD>BNA5<9;<9>9;L1<U ÅŸ=1<1A41;9"&81BC1<1AU>412D45B?>946?A=N<1BG?><1AU9<5 ÅŸu 
9BC5>=5G5>5C;9<5AG1GU><1>=UÅŸ CUA5A9=?A1A=1<1AUE5@>M=?>9  
 
 
ÅžN@85<914E5ABA51;B9G?><1AU>A1@?A<1>=1BU  
(D8B1C<1>4UA>1B?>A1BU ÅŸN@85<99<1L14E5ABA51;B9G?><1AU>U>A1@?A<1>=1BU2NGN;M>5=  
taÅŸU=1;C14UA(1@?A<1=1G1@U<=1BU9<13U>G1A1A	A9B;45>75B9>9>BNA5;<9?<1A1;9H<5>=5B9>5  
olanak saÄŸlar. SaÄŸ<U;=5B<5 ÄŸ9=5>BD@<1AU>U>85A81>7929A ÅŸN@85<914E5ABA51;B9G?>D*NA;9G5  
1A=1;?E9:9<1>B$5A;5H9*K$S>529<49A=5<5A975A5;=5;C549AFFFC9C3;7?ECA
eposta:  CD61=C9C3;7?ECAC5<





61;B
  
  
4.9. Doz a ÅŸI6I>.<.-*>2;2  
 Budesonidin akut toksisitesi dÃ¼ÅŸ N;4NH5G4549A"UB129ABNA59L5A9B9>45GN;B5;=9;C1A<1A41
9<13U>9>81<1BG?>D>DC1;925>?<DÅŸ 1>5>2NGN;H1A1A<U5C;989@?C1<1=9;- pitÃ¼iter -adrenal 
'6?>;B9G?><1AU>U>21B;U<1>=1BU4UAJH5<139<4DAD= M><5=<5A9>575A5;G?;CDABCU=U
;?>CA?<5C=5;9L9>M>5A9<5>4?H41 BUDERAT C541E9B9>5  45E1=549<=5<949A  
 
)CA5B4DAD=<1AU>4129AM><5=?<1A1;;?AC9;?BC5A?94<5A9>DG7D<1>=1BU75A5;<9?<129<9A
MA>5ÄŸ9>GN;B5;894A?;?AC9H?>4?H<1AU4A5>?;?AC9;1<1CA?69  7MAN<5>81BC1<1ABC5A?945
21ÄŸU=<U?<1A1;;12D<549<9AE54DAD=BC129<9H5?<1>1;141AG5C5A<9B9BC5=9;;?AC9;?BC5A?94
941=5C541E9B9>51G1A<1=1G1@U<=1<U4UA  
 5. FARMAKOLOJ Ä°K Ã–ZELLÄ° KLER  
 5.1. Farmakodinamik Ã¶zellikler  
 1A=1;?C5A1@MC9;7AD@&2s CAN;C96 akciÄŸ5A81BC1<U;<1AU9L9>49ÄŸ5A9<1L<1A9>81<1>C<1A
Glukokortikoidler  
*;?4D(

  
 D45B?>949>B1><1A4125<9A79>C?@9;1<5C;97MBC5A=5;<529A<9;C5M>5=<929AB9BC5=9;5C;9B9
?<=1G1>29A;?AC9;?BC5A?9449A9 ÄŸer inhale glukokortikoidlerde olduÄŸu 79292D45B?>9445
61A=1;?<?:9;5C;9<5A9>98N3A59L97<D;?;?AC9;?94A5B5@CMA<5A99<55C;9<5 ÅŸ5A5;7MBC5A9A9AL?;
61A;<UB9C?;9>;5=?;9>5>H9=E58N3A5145HG?>=?<5;N<N>N>NA5C9=99>8925549<9A"?AC9;?BC5A?94C541E9B9>45>61G417MA5>81BC1<1A419>81<1BG?>C?HD?<1A1;;D<<1>U<4U ÄŸU>41
75>5<<9;<5C541E9G521 ÅŸ<1>4U;C1>B?>A1
7N>9L5A9B9>451BCU=U;?>CA?<1<CU>11<129<=5;C549A
D45B?>944NH5><9;D<<1>U<4U ÄŸU>411BCU=<U1;39ÄŸ5A<5A45;9;A?>9;5>6<1=1BG?>D
1H1<C=1;C14UAD45B?>941GAU311;39 ÄŸ5A6?>;B9G?><1 AU>U1ACUA=1;C1E51BCU=B5=@C?=<1AU>U>
E52A?>ÅŸ  aÅŸUAU35E1@<U<UÄŸU>U>1H1<=1BU>UB1 ÄŸ<1=1;C11BCU= 1C1;<1AU>UM><5=5;C549A  
 5.2. Farmakokinetik Ã¶zellikler  
 Genel Ã¶zellikler  
 Emilim:  
AkciÄŸere ulaÅŸ 1>2D45B?>94 =9;C1AU8UH<U29A ÅŸ5;9<45E5C1=1=5>5=9<=5;C549A+G7D<1=141>
hemen sonra plazmada en yÃ¼ksek konsantrasyona ula ÅŸU<=1;C14UA&A?61A5>;BC5;1<1>4?H
9L9>75A5;<94NH5<C=5G1@U<4U;C1>B?>A1=DC<1;29G?G1A1A<1>U=?A1>U>414UA 
 
 
9 
 KaraciÄŸ5A45;925<9A79>@A5B9 BC5=9;=5C12?<9H=1>545>9G<59>81<5549<5>29A4?HD>GDCD<1>
6A1;B9G?>D>D>B14535
9<1SN29G?G1A1A<1>U=1B189@C9A9 ÄŸ5A2D45B?>94;DADC?H
9>81<5A<5A9<57MH<5>49 ÄŸ97929M>5A9<5>4?H1A1<U ÄŸU>41 BUDERAT S45>;1G>1;<1>1>B9BC5=9;
2D45B?>94=1ADH9G5C 9>9>4?H1?A1>CU<U?<=1BU25;<5>529<9A  
 
 
DaÄŸU<U=  
D45B?>949>@<1H=1@A?C59>9>521 ÄŸ<1>=1BU9<1

>=?<S<N;29A;?>B1>CA1BG?>1A1<U ÄŸU>41
-
S4UAD45B?>944?;D<1A1G1G7U>?<1A1;41 ÄŸU<UA;1A1A<U4DAD=4141 ÄŸU<U=813=9
9<1
#S49AGAU31G1 klaÅŸU;
BNC -@<1H=1;?>B1>CA1BG?>?A1>U9<51>>5BNCN>575L5A
525ÄŸin maruz kalacaÄŸUC18=9>97N><N;4?H7N><N;=1C5A>1<4?HD>G1;<1 ÅŸU;
SN4NAE5
2525;<5A45C18=9>9?AC1<1=1@<1H=1;?>B1>CA1BG?>D>2525;C5?A1<29G?G1A1A<1>U=U>C1=olacaÄŸUE1AB1GU<4 UÄŸU>414189=1C5A>1<@<1H=1;?>B1>CA1BG?>D>D>	

S4DA  
1GE1>L1<U ÅŸ=1<1AU>4141<1;<5>625H<5A9C9=DB14A5>1<;?AC5;BNA5=5?A71><1AUE5
2A?>ÅŸ<1A41GN;B5;;?>B1>CA1BG?><1A7MBC5A9<=9 ÅŸC9AD45B?>9461A545@<1B5>C121A9G5A9>9
geÃ§mektedir.  
 
BiyotranB6?A=1BG?>  
Budesonid akci ÄŸ5A<5A45=5C12?<9H5?<=1H=9<9=9>9C1;925>;1A139ÄŸ5A45GU;U=1D ÄŸA1AE5
25C1-894A?;B92D45B?>94E51<61 -894A?;B9@A54>9H?<?>4189<?<=1;NH5A529A49H99>1;C96
=5C12?<9C5<45549<9A  
 
D45B?>949>1>1=5C12?<9H=1G?<D-' 1A13U<UÄŸUG<14UAE52D45B?>94=5C12?<9H=1BU2D
5>H9=9>29<9>5>9>8929CMA<5A9G1419>4N;<5G939<5A9C1A16U>41>5C;9<5>529<9A;HM<N=  
 
Eliminasyon:  
RadyoiÅŸ1A5C<92D45B?>94B?<DG1>9>B1>7M>N<<N<5A45M<LN<N4?H9>81<5A9<5DG7D<1>1>4?HD>
yaklaÅŸU;SB994A1A41E54?HD>S965L5BC575A9;1H1>U<UA Ä°nhalasyondan sonra idrarda 
16-1<61-hidroksiprednizolon tespit edilmi ÅŸ2D45B?>94B1@C1>=1=U ÅŸCUA 
 
D45B?>949>CA1E5>MH4?HDG7D<1=1BU>UC1;925>GN;B5;@<1H=1;<5A5>B9#	B7MBC5A9A
Eliminasyo >G1AU<1>=1M=ANG1;<1 ÅŸU;9<1B11CC9A  
 DoÄŸADB1<<U;	? ÄŸrusal olmayan durum:  
DoÄŸADB1<<U;	4? ÄŸrusal olmayan duruma ili ÅŸ;9>=5E3DCE5A92D<D>=1=1;C14UA  
 *;<*5*:-*424*:*4<.:2;<24E@.55245.:  
 KaraciÄŸer yetmezli ÄŸi:  
Ä°>81<52D45B?>9461A=1;?;9>5C9 ÄŸi, karaciÄŸer yetmezli ÄŸ9?<1>81BC1<1A41L1<U ÅŸU<=1=UÅŸ CUA
>31;B9A?H81BC1<1AU>41;9?A1<DG7D<1=1>U>1A4U>41>2D45B?>949>B9BC5=9;G1A1A<1>U=U>U>
saÄŸ<U;<U;?>CA?<<5A57MA5;1C4181GN;B5;?<4DÄŸ D29<49A9<=9ÅŸ C9A1696;1A139 ÄŸer 
yetmezliÄŸ9>9>?A1<2D45B onidin sistemik maruziyet Ã¼zerinde az etkisi oldu ÄŸD29<49A9<=9ÅŸ tir.  
 
M2A5;G5C=5H<9 ÄŸi:  
D45B?>9461A=1;?;9>5C9 ÄŸ92M2A5;G5C=5H<9 ÄŸ9?<1>81BC1<1A41L1<U ÅŸU<=1=UÅŸ ?<=1;<129A<9;C5
M>5=<929A5C;925;<5>=5=5;C549AD>D><129A<9;C52D45B?>94=5C12?<9C<5A9 idrar yoluyla 
1CU<=1;C14UAE5 ÅŸ9445C<92M2A5;G5C=5H<9 ÄŸ9>45=5C12?<9C<5A9>29A9;=5B9>521 ÄŸ<U?<1A1;14E5AB
?<1G<1AU>7MAN<=5B9>45;91AC=U ÅŸA9B;?<1BU<UÄŸU7MH1A4U549<5=5=5;C549A  
  
 
 
10 
 '549G1CA9;@?@N<1BG?>  
D45B?>949>61A=1;?;9>5C9 ÄŸi @5491CA9;@?@N<1BG?>41L1<U ÅŸU<=1=UÅŸ CUA>31;49 ÄŸer inhale 
2D45B?>94NAN><5A9>5419AE5A9<5AG1 ÅŸU>NH5A9>45;9L?3D;<1A412545>1 ÄŸUA<UÄŸU>1>?A=1<9H5
edilen klirensin, yeti ÅŸ;9><5A5;UG1B<1G1;<1 ÅŸU;
4181GN;B5;?<4DÄŸD>D7MBC5A=5;C549A  
 
 
Geriyatrik popÃ¼lasyon:  
D45B?>949>61A=1;?;9>5C9 ÄŸi yaÅŸ<U81BC1<1A41L1<U ÅŸU<=1=UÅŸ CUA>31;G1 ÅŸE5NH5A9
81BC1<1A1419ABU>UA<UE5A9<5A?A1<E59>CA1E5>MHDG7D<1=1BU>UC1;925>418175>LG5C9 ÅŸkinler 
ile karÅŸU<1ÅŸCUAU<4UÄŸU>4161A=1;?;9>5C9;C51><1=<U29A61A;<U<U; 7MBC5A=5=5;C549A  
 
 
 A;39>B9G5C  
 A;G14139>B9G5C521 ÄŸ<U61A=1;?;9>5C9;61A;<U<U;<1AC1>U=<1>=1=UÅŸ CUA 
 
"<9>9;L1<UÅŸ malar:  
BUDERAT ile G1;U>H1=1>4129A;<9>9;L1<U ÅŸma gerÃ§ekleÅŸ tirilmemiÅŸ tir.  
 
52724E7,.;20F>.752524>.:25.:2  
 %.4:*:5I8@ Toksisitesi  
*5;A1A<U4?HC?;B9B9C5B9L1<UÅŸ =1<1AU>41>75<5>;<9>9;M>35B9E5A9<5AM>5A9<5>C5A1@MC9;4?H41
9>B1><1A9L9>MH5<29AC58<9;57MBC5A=5=9ÅŸ tir.  
 Mutajenisite ve Karsinojenisite  
9A49H99>E9CA?E59>E9E?=DC1:5>9B9C5C5BC9>452D45B?>949>=D tajenik potansiyele sahip 
?<=14UÄŸU7MBC5A9<=9ÅŸ tir.  
 
&A1<G?<<1DG7D<1>1>2D45B?>949>7N>45=9;A?7A1=	;7	7N>4?H4NH5G<5A9>45>9C921A5>
5A;5;BUL1><1A41;1A139 ÄŸ5ACN=MA<5A99>B941>BU>U1ACCUA4UÄŸU7MH<5>=9 ÅŸC9AD5C;9<5A1GAU31
21ÅŸka steroidleri (predn9H?<?>E5CA91=B9>?<?>1B5C?>949L5A5>29AC1;9@L1<UÅŸ =1BU>4141
7MH<5>=9ÅŸC9AE5;?AC9;?BC5A?94<5A9>DG7D<1=1BU9<59<9ÅŸ ;9<929ABU>U65C;9B9? lduÄŸD;12D<
edilmiÅŸ tir.  
 
Ãœreme toksisitesi  )D2;DC1>DG7D<1>1>2D45B?>949>BUL1>G1EAD<1AU>U>G1 ÅŸama yeteneÄŸi Ã¼ H5A9>45;91H1<CU3U
5C;9<5A9E52D45B?>949>BUL1><1A41;91>>5G5MH7NC?;B9B9C5B9C1EÅŸ anlardaki teratojenik 
@?C1>B9G5<9E52NGN=575A9<9 ÄŸ9NH5A9>45;95C;9<5A9E565C1<M<N=7<D;?;?AC9;?94<5A9>
81GE1><1A41;929<9>5>C5A1C?:5>9;@?C1>B9G5<99<5DGD=<D4DADdesonidin insanlarda 85A81>7929AC5A1C?:5>9C5G141NA5=5C?;B9B9C5B97MBC5A49 ÄŸine iliÅŸ ;9>29A;1>UCG?;CDA;H
M<N=)UL1><1A41BD2;DC1>G?<<1DG7D<1>1>2D45B?>949>65AC9<9C5NH5A9>4514E5AB29A5C;9B9?<=1=UÅŸ CUA 
 #$B% Ä°K Ã–ZELLÄ° KLER  
 	(*:-I6,I6*--.5.:2752;<.;2  
Laktoz monohidrat.  9>5;BNCN;1G>1;<U4UA   
Jelatin kapsÃ¼l iÃ§eri ÄŸi: Jelatin BU ÄŸUA;1G>1;<U4UA  
   
 
 
11 
 
.D26;2@5245.:  
Bilinen geÃ§imsizliÄŸi yoktur.  
 
#*/E6:F  
 ay  
 
$*45*6*?*?E7.524E@.5<.-+2:5.:  
O1<CU>41;9?41BU31;<U ÄŸU>41B1;<1GU>UH  
 
6+*5*3I772<.52 ÄŸ2>.2D.:2 ÄŸi  
',	',	<D=9>GD=2<9BC5A9L9>45
9>81<5A;1@BN<E5G1>U >4129A9>81<5A9L5A9A  
 
.ÅŸ.:2<I++2F:F7-.7*:<*4*5*76*--.5.:27261*;I>.-2 ÄŸer Ã¶zel Ã¶nlemler  
"D<<1>U<=1=U ÅŸ?<1>NAN><5AG1411CU;=1C5AG1<<5AQ*U229CU;<1AU>"?>CA?<N-M>5C=5<9 ÄŸ9R
E5Q=21<1:E5=21<1:CU;<1AU>U>"?>CA?<N-M>5C=5<9ÄŸ9R>5DG7D>?<1A1;9=81
edilmelidir.  
 Q)?>;D<<1>=1C1A98975L=9 ÅŸE5G1;D<<1>U<=1G1>9<1L<1AULM@51C=1GU>UHI5EA5E5 Åžehircilik 
1;1><UÄŸU>3125<9A<5>5>C?@<1=1B9BC5=9>5E5A9>9HR   
 
Ä°<13U>DG7D>;D<<1>U=U>41>5=9>?<=1;9L9>9>81<5A9>;D<<1>U<=1BU4?;C?AE5G153H13U
C1A16U>41>81BC1G17MBC5A9<=5<949A"D<<1>U=19<9ÅŸ ;9>45C1G<U29<79;D<<1>=1C1<9=1CU>41
=5E3DCCDA!5<1C9>;1@ BN<N>@1AL1<1>129<535ÄŸ9>9E5;NLN;:5<1C9>@1AL1<1AU>U>9>81<1BG?>41>
sonra aÄŸUHE5G12? ÄŸ1H2M<75B9>5D<1 ÅŸ129<535ÄŸ9>981BC1<1AU>29<=5B9M>5=<949A1BC1G1
:5<1C9>9>H1A1ABUH?<4D ÄŸu, aÄŸUH41GD=DÅŸ ayacaÄŸUE5GDCD<129<49 ÄŸ9BMG<5>=5<949A"1@BN<N29A
456141>6 1H<145<=5=5;BDA5C9G<5@1AL1<1>=1?<1BU<U ÄŸU1B71A94NH5G59>49A9<529<9A  
"1@BN<;D<<1>=141>85=5>M>351=21<1:U>41>LU;1AU<=1<U4UA  
 #&$%$ Ä°BÄ°  
 AAU=54Ä°<1L)1>E5*93 Åž. 
KaÄŸUC81>5	Ä°BC1>2D<  
 
#&$% &#$  
 

	  
 9. Ä°#&$%%#Ä° Ä°#&$%( Ä° LEME TAR Ä°Ä°  
 Ä°lk ruhsat tarihi: 

   
Ruhsat yenileme tarihi: -   
 
	CHC ( Ä° LENME TAR Ä°Ä° 